Needham analyst Gil Blum lowered the firm’s price target on Mereo BioPharma (MREO) to $5 from $7 but keeps a Buy rating on the shares. The company announced that the Phase 3 Orbit study will continue towards a final analysis expected in Q4 after missing on its second interim, and this outcome represents the firm’s downside scenario, though Needham’s overall view on setrusumab’s ultimate likelihood of success remains unchanged, given that about 80% alpha spend is reserved for the final analysis, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO:
- Mereo BioPharma’s Phase 3 Study Progresses Smoothly
- Mereo Biopharma Group Plc: Buy Rating Maintained Amid Challenges and Promising Study Outcomes
- Promising Outlook for Mereo Biopharma’s Setrusumab Amid Phase 3 Trial Advances and Market Potential
- Closing Bell Movers: Ultragenyx slumps 25% on UX143 recommendation
- Ultragenyx, Mereo BioPharma receive DMC recommendation to continue Orbit study